Zhejiang Medicine CoSHSE:600216 -0.83%81 EBITDA Margin % is 14.21% as of Mar. 2026, which is 11% below its 10-year median of 15.93. GuruFocus rates SHSE:600216 with a GF Score™ of 81/100 and a GF Value™ of ¥13.81 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Zhejiang Medicine Co ranks worse than 58.05% on this metric.
Zhejiang Medicine Co (SHSE:600216) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zhejiang Medicine Co EBITDA Margin % Related Terms
Zhejiang Medicine Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zhejiang Medicine Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600216 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Medicine Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Medicine Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Medicine Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Medicine Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Medicine Co (SHSE:600216) has a EBITDA Margin % of 14.21% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhejiang Medicine Co and its competitors. This is 11% below median its historical median of 15.93. Over the past decade, Zhejiang Medicine Co's EBITDA Margin % has ranged from 9.40 to 20.92. According to the industry distribution chart, Zhejiang Medicine Co ranks #555 out of 956 companies in the Drug Manufacturers industry, placing it in the top 58.1%.
Is Zhejiang Medicine Co's EBITDA Margin % too high?
Zhejiang Medicine Co's current EBITDA Margin % of 14.21% is 11% below median its 10-year median of 15.93. Over the past 10 years, this metric has ranged from a low of 9.40 to a high of 20.92. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Zhejiang Medicine Co's value of 14.21% is 13.5% above this industry median. Based on the distribution chart, Zhejiang Medicine Co ranks #555 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhejiang Medicine Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Medicine Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zhejiang Medicine Co ranks #555 out of 956 companies for EBITDA Margin %. This places Zhejiang Medicine Co in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Zhejiang Medicine Co's value of 14.21% is 13.5% above this benchmark. Historically, Zhejiang Medicine Co's own EBITDA Margin % has ranged from 9.40 to 20.92 over the past decade. While the company's 10-year median is 15.93 vs. the industry median of 12.52, Zhejiang Medicine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Medicine Co's current EBITDA Margin % of 14.21% is 13.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhejiang Medicine Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Medicine Co's current EBITDA Margin % is 14.21%, which is 11% below median its own 10-year median of 15.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Medicine Co (SHSE:600216) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥13.81, compared to a current price of ¥12.00 — trading 13.1% below its estimated fair value. The current EBITDA Margin % is 14.21%, which is 11% below median its 10-year median of 15.93 and 13.5% above the Drug Manufacturers industry median of 12.52. Zhejiang Medicine Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zhejiang Medicine Co (SHSE:600216), the current EBITDA Margin % is 14.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Medicine Co (SHSE:600216) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Medicine Co stock appears to be undervalued.
The current stock price of ¥12.00 is trading 13.1% below its estimated GF Value™ of ¥13.81.
GuruFocus considers Zhejiang Medicine Co to be Modestly Undervalued.
Key valuation signals for SHSE:600216:
EBITDA Margin %: 14.21% (11% below median its 10-year median of 15.93)
GF Value™: ¥13.81 vs. price of ¥12.00 (13.1% below fair value)
Industry Position: 13.5% above the Drug Manufacturers median (#555 of 956)
No single metric tells the full story. See the SHSE:600216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
81GF Score
Get the complete analysis for SHSE:600216
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600216 has been successfully added to your 
